Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Thirty-seven patients with metastatic prostate cancer refractory to endocrine therapy were treated in a phase II trial of mitoxantrone. Starting doses were 12 and 10 mg/m2 iv every 21 days for good-risk and poor-risk patients, respectively. Of the 35 evaluable patients, two had objective partial regression and five had stable disease. Response duration ranged from 7 to 17+ months. The drug was very well tolerated by these elderly patients; myelosuppression was the major toxic effect. We conclude that mitoxantrone has modest activity and acceptable toxicity in patients with advanced prostate cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D000880:Anthraquinones; D008942:Mitoxantrone